Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.54 USD
Change Today -0.78 / -3.23%
Volume 84.8K
QURE On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 4:30 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

uniqure b.v. (QURE) Snapshot

Open
$24.32
Previous Close
$24.32
Day High
$24.44
Day Low
$22.84
52 Week High
03/20/15 - $28.00
52 Week Low
05/22/14 - $8.29
Market Cap
414.1M
Average Volume 10 Days
168.2K
EPS TTM
--
Shares Outstanding
17.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UNIQURE B.V. (QURE)

uniqure b.v. (QURE) Related Businessweek News

No Related Businessweek News Found

uniqure b.v. (QURE) Details

uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

87 Employees
Last Reported Date: 04/25/14
Founded in 1998

uniqure b.v. (QURE) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €480.0K
Compensation as of Fiscal Year 2013.

uniqure b.v. (QURE) Key Developments

uniQure N.V. Presents at BioCapital Europe 2015, Mar-26-2015 05:00 PM

uniQure N.V. Presents at BioCapital Europe 2015, Mar-26-2015 05:00 PM. Venue: Sofitel Legend Amsterdam, Amsterdam, Netherlands.

uniQure N.V. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 31, 2014

uniQure N.V. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenues were $1.001 million against $1.293 million a year ago. Operating result was $7.893 million against $5.386 million a year ago. Net loss was $9.059 million against $7.038 million a year ago. For the nine months, total revenues were $3.213 million against $2.051 million a year ago. Operating result was $24.270 million against $15.540 million a year ago. Net loss was $25.879 million against $19.962 million a year ago. Cash used in operating activities was $16.919 million against cash generated by operating activities of $1.654 million a year ago. Total capital expenditures was $16.957 million against $4.159 million a year ago.

uniQure Seeks Acquisitions

uniQure N.V. (NasdaqGS:QURE) stated in the Form F-3 filed on March 3, 2015, that it would use the proceeds for working capital and for general corporate purposes, including the costs of operating our facilities in Amsterdam and in Lexington, Massachusetts, service on their indebtedness and possibly acquisitions or investments in other businesses, technologies or product candidates.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QURE:US $23.54 USD -0.78

QURE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QURE.
View Industry Companies
 

Industry Analysis

QURE

Industry Average

Valuation QURE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 85.9x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 65.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNIQURE B.V., please visit www.uniqure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.